Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1359 ARTÍCULOS , VIENDO DEL 1246 AL 1260

[Patients at the memory clinic with choreatic movements]

Klompe LA, Eerenberg JG, Verschoor CJ.

Tijdschr Gerontol Geriatr. 2011 Feb;42(1):29-33.

Abnormal error-related antisaccade activation in premanifest and early manifest Huntington disease

Rupp J, Dzemidzic M, Blekher T, Bragulat V, West J, Jackson J, Hui S, Wojcieszek J, Saykin AJ, Kareken D, Foroud T.

Neuropsychology. 2011 May;25(3):306-18. doi: 10.1037/a0021873.

The role of CREB signaling in Alzheimer's disease and other cognitive disorders

Saura CA, Valero J.

Rev Neurosci. 2011;22(2):153-69. doi: 10.1515/RNS.2011.018.

The ethics of disclosing genetic diagnosis for Alzheimer's disease: do we need a new paradigm?

Arribas-Ayllon M.

Br Med Bull. 2011;100:7-21. doi: 10.1093/bmb/ldr023. Epub 2011 Jun 14.

Exploring the correlates of intermediate CAG repeats in Huntington disease

Ha AD, Jankovic J.

Postgrad Med. 2011 Sep;123(5):116-21. doi: 10.3810/pgm.2011.09.2466.

Huntington's disease: clinical presentation and treatment

Novak MJ, Tabrizi SJ.

Int Rev Neurobiol. 2011;98:297-323. doi: 10.1016/B978-0-12-381328-2.00013-4.

Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development

Ehrnhoefer DE, Wong BK, Hayden MR.

Nat Rev Drug Discov. 2011 Oct 21;10(11):853-67. doi: 10.1038/nrd3556.

Westphal variant Huntington disease and refractory catatonia: a case report

Merida-Puga J, Ramirez-Bermudez J, Aguilar-Venegas LC, Fricchione GL, Espinola-Nadurille M.

Cogn Behav Neurol. 2011 Dec;24(4):204-8. doi: 10.1097/WNN.0b013e318240080d.

Epigenetic treatment of neurological disease

Gray SG.

Epigenomics. 2011 Aug;3(4):431-50. doi: 10.2217/epi.11.67.

The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer's disease

da Rocha MD, Viegas FP, Campos HC, Nicastro PC, Fossaluzza PC, Fraga CA, Barreiro EJ, Viegas C Jr.

CNS Neurol Disord Drug Targets. 2011 Mar;10(2):251-70. doi: 10.2174/187152711794480429.

Neuronal hemoglobin is reduced in Alzheimer's disease, argyrophilic grain disease, Parkinson's disease, and dementia with Lewy bodies

Ferrer I, Gómez A, Carmona M, Huesa G, Porta S, Riera-Codina M, Biagioli M, Gustincich S, Aso E.

J Alzheimers Dis. 2011;23(3):537-50. doi: 10.3233/JAD-2010-101485.

Insights from Caenorhabditis elegans on the role of metals in neurodegenerative diseases

Martinez-Finley EJ, Avila DS, Chakraborty S, Aschner M.

Metallomics. 2011 Mar;3(3):271-9. doi: 10.1039/c0mt00064g. Epub 2011 Jan 6.

Implication of oncogenic signaling pathways as a treatment strategy for neurodegenerative disorders - contemporary approaches

Sieradzki A, Yendluri BB, Palacios HH, Parvathaneni K, Reddy VP, Obrenovich ME, Gąsiorowski K, Leszek J, Aliev G.

CNS Neurol Disord Drug Targets. 2011 Mar;10(2):175-83. doi: 10.2174/187152711794480410.

Pedophilic behavior from brain disease

Mendez M, Shapira JS.

J Sex Med. 2011 Apr;8(4):1092-100. doi: 10.1111/j.1743-6109.2010.02172.x. Epub 2011 Jan 14.

Granular expression of prolyl-peptidyl isomerase PIN1 is a constant and specific feature of Alzheimer's disease pathology and is independent of tau, Aβ and TDP-43 pathology

Dakson A, Yokota O, Esiri M, Bigio EH, Horan M, Pendleton N, Richardson A, Neary D, Snowden JS, Robinson A, Davidson YS, Mann DM.

Acta Neuropathol. 2011 May;121(5):635-49. doi: 10.1007/s00401-011-0798-y. Epub 2011 Jan 18.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias